DK1465617T3 - Fremgangsmåde til at påvirke neurologisk progression - Google Patents

Fremgangsmåde til at påvirke neurologisk progression

Info

Publication number
DK1465617T3
DK1465617T3 DK02799240T DK02799240T DK1465617T3 DK 1465617 T3 DK1465617 T3 DK 1465617T3 DK 02799240 T DK02799240 T DK 02799240T DK 02799240 T DK02799240 T DK 02799240T DK 1465617 T3 DK1465617 T3 DK 1465617T3
Authority
DK
Denmark
Prior art keywords
influencing
procedures
neurological progression
neurological
progression
Prior art date
Application number
DK02799240T
Other languages
English (en)
Inventor
Richard A Miller
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Application granted granted Critical
Publication of DK1465617T3 publication Critical patent/DK1465617T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • A61K47/546Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK02799240T 2001-12-13 2002-12-12 Fremgangsmåde til at påvirke neurologisk progression DK1465617T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33965001P 2001-12-13 2001-12-13
US34658402P 2002-01-07 2002-01-07
US35309002P 2002-01-30 2002-01-30
PCT/US2002/039974 WO2003049731A1 (en) 2001-12-13 2002-12-12 Process for affecting neurologic progression

Publications (1)

Publication Number Publication Date
DK1465617T3 true DK1465617T3 (da) 2009-02-16

Family

ID=27407352

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02799240T DK1465617T3 (da) 2001-12-13 2002-12-12 Fremgangsmåde til at påvirke neurologisk progression

Country Status (16)

Country Link
US (1) US20030130252A1 (da)
EP (1) EP1465617B1 (da)
JP (1) JP2005511719A (da)
KR (1) KR20040075001A (da)
CN (1) CN1615129A (da)
AT (1) ATE411017T1 (da)
AU (1) AU2002364165B2 (da)
CA (1) CA2469613A1 (da)
DE (1) DE60229437D1 (da)
DK (1) DK1465617T3 (da)
ES (1) ES2315429T3 (da)
IL (1) IL162469A0 (da)
MX (1) MXPA04005715A (da)
PL (1) PL372326A1 (da)
PT (1) PT1465617E (da)
WO (1) WO2003049731A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006206398A1 (en) * 2005-01-19 2006-07-27 Pharmacyclics, Inc. A method for treating neurologic diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5776925A (en) * 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer

Also Published As

Publication number Publication date
EP1465617A1 (en) 2004-10-13
US20030130252A1 (en) 2003-07-10
AU2002364165B2 (en) 2007-09-20
CA2469613A1 (en) 2003-06-19
PT1465617E (pt) 2009-01-23
ATE411017T1 (de) 2008-10-15
KR20040075001A (ko) 2004-08-26
ES2315429T3 (es) 2009-04-01
IL162469A0 (en) 2005-11-20
CN1615129A (zh) 2005-05-11
WO2003049731A1 (en) 2003-06-19
PL372326A1 (en) 2005-07-11
DE60229437D1 (de) 2008-11-27
EP1465617B1 (en) 2008-10-15
AU2002364165A1 (en) 2003-06-23
MXPA04005715A (es) 2004-10-15
JP2005511719A (ja) 2005-04-28
EP1465617A4 (en) 2005-10-12

Similar Documents

Publication Publication Date Title
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
UA85559C2 (en) Aminobenzophenone compounds
BR0213424A (pt) Uso aperfeiçoado de composto antitumoral na terapia contra câncer
PL369530A1 (en) Chemical compounds
SV2003001076A (es) Compuestos y procedimientos antitumorales ref. x-14776
IS6964A (is) Ónæmismeðferðarsamsetningar til meðhöndlunar á æxlum sem oftjá ganglíósíð
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
AU2003300385A8 (en) Anticancer compounds
AP2003002753A0 (en) Use of salmeterol and fluticasone propionate combination
SI1831209T1 (sl) Zaviralci fosfataz cdc25
HUP0402341A3 (en) Compositions containing thiazol-2-ylamines for the treatment of cancer
DK1465617T3 (da) Fremgangsmåde til at påvirke neurologisk progression
MXPA03006412A (es) Metodos para administrar analogos de epotilona para tratamiento de cancer.
SE0002739D0 (sv) New use
BRPI0607285A2 (pt) tratamento de tumores com metástases
MXPA04003910A (es) Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar.
HN2002000335A (es) Compuestos asapoliciclicos condensados con arilo
MXPA03006866A (es) Modificacion cristalina de depsipeptido ciclico con actividad mejorada.
PT1427420E (pt) Utilizacao de uma combinacao compreendendo 4- piridilmetilftalazinas para o tratamento do cancro
MXPA04006085A (es) Compuestos de isocromano para el tratamiento de trastornos del sistema nervioso central.
CA97933S (en) Hose clamp
WO2003035104A3 (en) Compositions and methods for selected tumor treatment
TW200613301A (en) Novel amino-halogen-imidazopyridines
WO2004037211A3 (en) Taxane metabolites
PA8557301A1 (es) Compuestos retinoides heterociclicos